High-risk (HR) pediatric acute lymphoid leukemias (ALL) B and T cells have poor prognosis: a complete remission can be achieved with complex protocols1. In this study, the rMnSOD action was tested on pediatric B and T high-risk ALL cells. LSA-rMnSOD, the recombinant isoform of SOD secreted by liposarcoma, exerts an oncosuppressive action5. The internalization of rMnSOD at scalar concentrations (20- 0.2 μg/mL) in leukemic cells was demonstrated by LM and TEM immunocytochemistry. Proliferation tests was studied by TB and MTT assay. The intense immunolabeling after 20 μg/mL rMnSOD-treatment decreased as concentrations were reduced. Early signs of apoptosis were detectable with a major modulation of proapoptotic Bax and a negative modulation of anti apoptotic Bcl-2. Conversely, we observed in ALL B-HR a down phosphorylation of AKT and ERK respect to diagnosis, with a decrease in proliferation (MTT= 27%). In ALL T-HR none significative variation was observed after treatment. Thus, rMnSOD enters in leukemic cells, suppressing, by high concentrations of H2O2, their proliferation 6. Biomolecular detection of apopototic proteins showed that the 2μg/mL was most effective dose of rMnSOD able to trigger apoptosis of leukemic cells. rMnSOD could become an innovative anti-cancer drug for treatment of high-risk leukemia in emerging target therapies because of its action in pro survival signaling.
Immunocytochemical detection of rMnSOD and apoptosis in high-risk pediatric leukemia cells / DI SANTI, Annalisa; Basile, Filomena; V., D'Angelo; A., Iannotta; M., Ramaglia; A., Borrelli; A., Schiattarella; P., Indolfi; F., Casale; A., Mancini; Pica, Alessandra. - In: EUROPEAN JOURNAL OF HISTOCHEMISTRY. - ISSN 1121-760X. - Vol 55, No 1s (2011):1(2011), pp. 16-16. (Intervento presentato al convegno 34° Congresso Società Italiana di Istochimica tenutosi a S. Benedetto del Tronto nel 7-9 giugno 2011).
Immunocytochemical detection of rMnSOD and apoptosis in high-risk pediatric leukemia cells
DI SANTI, ANNALISA;BASILE, FILOMENA;PICA, ALESSANDRA
2011
Abstract
High-risk (HR) pediatric acute lymphoid leukemias (ALL) B and T cells have poor prognosis: a complete remission can be achieved with complex protocols1. In this study, the rMnSOD action was tested on pediatric B and T high-risk ALL cells. LSA-rMnSOD, the recombinant isoform of SOD secreted by liposarcoma, exerts an oncosuppressive action5. The internalization of rMnSOD at scalar concentrations (20- 0.2 μg/mL) in leukemic cells was demonstrated by LM and TEM immunocytochemistry. Proliferation tests was studied by TB and MTT assay. The intense immunolabeling after 20 μg/mL rMnSOD-treatment decreased as concentrations were reduced. Early signs of apoptosis were detectable with a major modulation of proapoptotic Bax and a negative modulation of anti apoptotic Bcl-2. Conversely, we observed in ALL B-HR a down phosphorylation of AKT and ERK respect to diagnosis, with a decrease in proliferation (MTT= 27%). In ALL T-HR none significative variation was observed after treatment. Thus, rMnSOD enters in leukemic cells, suppressing, by high concentrations of H2O2, their proliferation 6. Biomolecular detection of apopototic proteins showed that the 2μg/mL was most effective dose of rMnSOD able to trigger apoptosis of leukemic cells. rMnSOD could become an innovative anti-cancer drug for treatment of high-risk leukemia in emerging target therapies because of its action in pro survival signaling.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
